Trial · NCT07904650
PRP Versus Saline Hydrodissection for CTS RCT
NCT07904650, Phase 4, Completed, Medical University of Lodz
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PRP Versus Saline Hydrodissection for CTS RCT. Trials, record NCT07904650. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904650
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PRP Versus Saline Hydrodissection for CTS RCT
- NCT number
- NCT07904650
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 21 participants, actual
- Lead sponsor
- Medical University of Lodz
- Conditions
- Carpal Tunnel Syndrome (CTS)
- Interventions
- Autologous platelet-rich plasma, Normal Saline (0.9% Sodium Chloride), Ultrasound-guided median nerve hydrodissection
- First posted
- 2026-10-29
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS) | Baseline, 3 months and 6 months after the intervention | Self-administered 11-item scale assessing the severity of carpal tunnel syndrome symptoms. Each item is scored from 1 to 5, and the subscale score is calculated as the mean of the items (range 1.00-5.00), with higher scores indicating greater symptom severity. The validated Polish version was used. |
| Primary | Boston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS) | Baseline, 3 months and 6 months after the intervention | Self-administered 8-item scale assessing difficulty in performing daily activities. Each item is scored from 1 to 5, and the subscale score is calculated as the mean of the items (range 1.00-5.00), with higher scores indicating greater functional disability. The validated Polish version was used. |
| Secondary | Neuropathic pain - Douleur Neuropathique 4 (DN4) questionnaire | Baseline, 3 months and 6 months after the intervention | Clinician-administered questionnaire consisting of 7 interview items and 3 examination items. Total score ranges from 0 to 10; a score of 4 or more indicates probable neuropathic pain. Higher scores indicate more neuropathic pain features. |
| Secondary | Median nerve cross-sectional area (CSA) | Baseline, 3 months and 6 months after the intervention | Cross-sectional area of the median nerve (mm2) measured on ultrasound in the transverse plane at the carpal tunnel inlet (pisiform-scaphoid level) by continuous tracing inside the hyperechoic epineurium. The mean of three measurements was recorded. |
| Secondary | Peak force of hand grip, pinch grip and thumb flexion | Baseline, 3 months and 6 months after the intervention | Peak force (N) for hand grip, pinch grip and thumb flexion measured with the VALD DynaMo dynamometer. |
| Secondary | Time to peak force of hand grip, pinch grip and thumb flexion | Baseline, 3 months and 6 months after the intervention | Time to peak force (s) for hand grip, pinch grip and thumb flexion measured with the VALD DynaMo dynamometer. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904650
GET https://conductscience.org/api/trials/v1/NCT07904650/registered